A common mutation in a key enzyme involved in alcohol metabolism may increase damage in cells obtained from individuals with Alzheimer’s disease and in mice.
At the Clinical Trials on Alzheimer’s Disease Congress this week, Biogen (MA, USA) has provided a detailed report on the latest aducanumab results, including why there was such a difference in the results between ENGAGE and EMERGE.
A recent set of studies reports how blood–brain barrier leakage may affect inflammation in the brain, potentially leading to acceleration of neurological aging in mice.
Sex-specific effects of microbiome perturbations in an Alzheimer’s mouse model: an interview with Hemraj Dodiya
At SfN Neuroscience 2019, we had the brilliant opportunity of interviewing Hemraj Dodiya about sex-specific effects of microbiome perturbations in an Alzheimer’s mouse model.
Preclinical data has demonstrated that an oral small molecule drug could inhibit the formation of neurotoxic tau oligomers in an animal model most relevant to Alzheimer’s disease.
What are the challenges associated with identifying risk genes for Alzheimer’s disease? What more needs to be done to successfully translate this genetic data into potential therapeutics? Watch our video with Owen Peters to find out more.
What might the mechanisms behind circadian dysfunction in the early stages of dementia be? What more needs to be done to successfully translate this into the clinic? Watch our video with Marco Brancaccio to find out.
At the UK–Korea Neuroscience Symposium (12–13 August, London, UK), we had the fantastic opportunity of…
Chinese pharmaceutical firm, Shanghai Green Valley Pharmaceuticals, has gained conditional approval from the country’s regulatory agency for oligomannate as a treatment for mild-to-moderate Alzheimer’s disease.
A woman genetically predisposed to have early-onset autosomal dominant Alzheimer’s disease at the age of 40 did not display symptoms until her 70s. This has been linked to the presence of a rare gene variant termed APOE3ch.